1. Czapinski P, Blaszczyk B. Mechanisms of Action of Antiepileptic Drugs. Curr Top Med Chem. 2005;5:3–15.
2. Rajput SK, Singh JN, Ingole S, et al. Neuropharmacological profile of L-pGlu-(1-benzyl)- L-His-L-ProNH2, a newer thyrotropin-releasing hormone analog: Effects on seizure models, sodium current, cerebral blood flow and behavioural parameters. Epilepsy Res. 2009;87:223–33.
3. Andreas V. Alexopoulos. Pharmacoresistant epilepsy: Definition and explanation. Epileptology. 2013;1:38–42.
4. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult Epilepsy. Lancet. 2006;367:1087–187.
5. Arts WF, Brouwer OF, Peters AC, et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain. 2004;127:177–484.
6. Mohanraj R, Brodie M. Diagnosing refractory epilepsy: response to sequential treatment schedule. Eur J Neurol. 2006;13:277–82.
7. Kwan P, Schchter S, Brodie M. Drug resistant epilepsy. N Engl J Med. 2011;365:919–26.
8. Stepien MK, Tomaszewski M, Tomaszewski J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep. 2012;64:1011–9.
10. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP binding cassette gene family. Neuro Rx. 2005;2:86–98.
11. Sisodiya SM, Martinian L, Scheffer SL, et al. Drug resistance in epilepsy: Is the role of underlying pathology related to multidrug resistance protein. Epilepsia. 2003;44:1388–96.
12. Zhang Z, Wu JY, Hait WN, Yang JM. Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol. 2004;66:395–403.
13. Kwan P, Brodie MJ. Potential role of drug transporters in pathogenesis of medically intractable epilepsy. Epilepsia. 2005;46:224–35.
14. Ak H, Ay B, Tanriverdi T, et al. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure. 2007;16:493–503.
15. Aronica E, Gorter JA, Ramkema M, et al. Expression and cellular distribution of multidrug resistance related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia. 2004;45:441–51.
16. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2001;42:1501–6.
17. Kubota H, Ishihara H, Langmann T, et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res. 2006;68:213–28.
18. Lazarowski A, Lubieniecki F, Camarero S, et al. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol. 2004;30:102–6.
19. Losher W. Drug transporters in the epileptic brain. Epilepsia. 2007;48:8–13.
20. Pfeifer HH, Thiele EA. Low-glycaemic-index treatment: a liberalized Ketogenic diet for treatment of intractable epilepsy. Neurolog. 2005;65:1810–2.
21. Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals. 2010;3:2090–110.
22. Czuczwar P, Kaczmarczyk K, Wierzchowska-Cioch E, Łuszczki JJ, Czuczwar SJ. Drug resistance in epilepsy. Przegl Lek. 2009;66:963–6.
23. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain. 2006;129:18–35.
24. Rogaswaki MA, Bazil CW. New molecular targets for antiepileptic drugs. Curr Neurol Neurosci. 2008;8:345–52.
25. Muguire M, Marson A, Ramaratnam S. Epilepsy (generalised). Clinical Evidence. 2012;2012:1201
26. Straessle A, Loup F, Ohning GV, Arabadzisc D, Fritschy JM. Rapid and long term alterations of hippocampal GABAB receptors in a mouse model of temporal lobe epilepsy. Eur J Neurosci. 2003;18:2213–26.
27. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9.
28. Greene AE, Todorova MT, Seyfried TN. Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. J Neurochem. 2003;86:529–37.
29. Nicita F, Spalice A, Papetti L, Nikanorova M, Iannetti P, Parisi P. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure. 2014;23:36–40.
30. Funck VR, de Oliveira CV, Pereira LM, et al. Differential effects of atorvastatin treatment and withdrawal on Pentylenetetrazole-induced seizures. Epilepsia. 2011;5:2094–104.
31. Moezi L, Shafaroodi H, Hassanipour M, Fakhrzad A, Hassanpour S, Dehpour AR. Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of nitric oxide. Epilepsy Behav. 2012;23:399–404.
32. Moazzami K, Emamzadeh-Fard S, Shabani M. Anticonvulsive effect of atorvastatin on pentylenetetrazole-induced seizures in mice: the role of nitric oxide pathway. Fundam Clin Pharmacol. 2013;27:387–92.
33. Lee JK, Won JS, Singh AK, Singh I. Statin inhibits kainic acid induced seizure and associated inflammation and hippocampal cell death. Neurosci Lett. 2008;440:260–4.
34. Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair. Exp Neurol. 2012;238:265–72.
35. Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibres in patients with temporal lobe epilepsy. J Neurosci. 2001;21:5804–12.
36. Furtinger S, Pirker S, Czech T, Baumgartner C, Sperk G. Altered expression of neuropeptide Y, -Y (1), and -Y (2) receptors in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43:152
37. Kokaia M. Seizure-induced neurogenesis in the adult brain. Eur J Neurosci. 2011;33:1133–8.
38. Yao D, Liu L, Jin S, Li J, Liu XD. Over expression of multidrug resistance associated protein-2 in the brain of Pentylenetetrazole Kindled Rats. Neuroscience. 2012;227:283–92.
39. Dong C, Zhao W, Li W, Lv P, Dong X. Anti-epileptic effects of neuropeptide Y gene transfection into the rat brain. Neural Regen Res. 2013;8:1307–15.
40. Gouder N, Fritschy JM, Detlev B. Seizure Suppression by Adenosine A1 Receptor Activation in a mouse Model of Pharmacoresistant Epilepsy. Epilepsia. 2003;44:877–85.
41. Jaworska-Feil L, Kajta M, Budziszewska B, Leskiewicz M, Lason W. Protective effects of TRH and its stable analogue, RGH-2202, on kainate-induced seizures and neurotoxicity in rodents. Epilepsy Res. 2001;43:67–73.
42. Przewłocka B, Labuz D, Mika J, et al. Protective effects of TRH and its analogues in chemical and genetic models of seizures. Pol J Pharmacol. 1997;49:373–8.
43. Potschka H. Modulating P-Glycoprotein Regulation: Future perspectives for Pharmacoresistant Epilepsies. Epilepsia. 2010;51:1333–47.
44. Kubek MJ, Garg BP. Thyrotropin-releasing hormone in the treatment of intractable epilepsy. Pediatr. Neurol. 2002;26:9–17.
45. Deng PY, Porter JE, Shin HS, Lei S. Thyrotropin-releasing hormone increases GABA release in rat hippocampus. J Physiol. 2007;497:511
46. Pati S, Alexopoulos AV. Pharmacoresistant epilepsy: From pathogenesis to current and emerging therapies. CCJM. 2010;77:7
47. Mitchell J, Seri S, Cavanna A. Pharmacotherapeutic and non-pharmacological options for refractory and difficult-to-treat seizures. J Cent Nerv Syst Dis. 2012;4:105–15.
48. Schachter SC, Saper CB. Vagus nerve stimulation. Epilepsia. 1998;39:677–86.
49. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51:899–908.
50. Burton JM, Peebles GA, Binder DK, Rothman SM, Smyth MD. Transcortical cooling inhibits hippocampal-kindled seizures in the rat. Epilepsia. 2005;46:1881–7.
51. Javedan SP, Fisher RS, Eder HG, Smith K, Wu J. Cooling abolishes neuronal network synchronization in rat hippocampal slices. Epilepsia. 2002;43:574–80.
52. Yang XF, Chang JH, Rothman SM. Long-lasting anticonvulsant effect of focal cooling on experimental neocortical seizures. Epilepsia. 2003;44:1500–5.
53. Bough KJ, Schwartzkroin PA, Rho JM. Calorie restriction and ketogenic diet diminish neuronal excitability in rat dentate gyrus in vivo. Epilepsia. 2003;44:752–60.
54. Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20:359–68.
55. Neal EG, Chaffe H, Schwartz RH, et al. The Ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7:500–6.
56. Schwartz RH, Eaton J, Bower BD, Aynsley-Green A. Ketogenic diets in the treatment of epilepsy: short-term clinical effects. Dev Med Child Neurol. 1989;31:145–51.
57. Schachter SC. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics. 2009;6:415–20.
58. Ekstein D, Schachter SC. Natural products in epilepsy-the present situation and perspectives for the future. Pharmaceuticals. 2010;3:1426–45.